References
1. Parker SL, Tong T, Bolden S, Wingo PA.
Cancer statistics, 1997. CA 1997;47:5-27.
2. Feuer EJ, Wun L-M, Bering CC, et al. J Natl
Cancer Instit 1993;85:892.
3. Menck HR, Henderson BE. Cancer incidence
rates in the Pacific Basin. Natl Cancer Instit
Monogr 1979;53:119-124.
4. Dupont WD, Page DL. Breast cancer risk
associated with proliferative disease, age at
first birth, and family history of breast cancer.
Am J Epidem 1987;125:769-779.
5. Yager JD. Liehr JG. Molecular mechanisms of
estrogen carcinogenesis. Annual Review of
Pharmacology & Toxicology. 36:203-32, 1996.
6. Petrakis NL. Breast Cancer. In: "The
Genetic Basis of Common Diseases."
7. Claus EB, Risch N, Thompson WD. Autosomal
dominant inheritance of early-onset breast
cancer. Cancer 1994;73:643-651.
8. Harvald B, Hauge M. Heredity of cancer
elucidated by a study of unselected twins. JAMA
1963;186:749-753.
9. Claus EB, Risch N, Thompson WD. Genetic
analysis of breast cancer in the cancer and
steroid hormone study. Am J Hum Genet
1991;48:232-242.
10. Hoskins KF, Stopfer JE, Calzone KA,
Merajver SD, Rebbeck TR, Garber JE, Weber BL.
Assessment and counseling for women with a family
history of breast cancer. A guide for clinicians.
JAMA 1995;273:577-585.
11. Hall JM, Lee MK, Newman B. Morrow JE,
Anderson LA, Huey B, King M-C. Linkage of early
onbset familial breast cancer to chromosome
17q21. Science 1990;250:1684-1689.
12. Wooster R, Neuhausen S, Manigion J, Quirk
Y, Ford D, Collins N, Nguyen K, Seal S, Tran T,
Averill D, Fields P, Marshall G, Narod S, Lenoir
GM, Lynch H, Feunteun J, Devilee P, Cornelisse
CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye
C, Lewis CM, Cannon-Albright LA, Peto J, Ponder
BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton
MR. Localisation of a breast cancer
susceptibility gene (BRCA2) to chromosome 13q by
genetic linkage analysis. Science
1994;265:2088-2090.
13.Ford D, Easton DF. The genetics of breast
and ovarian cancer. Br J Cancer 1995;72:805-812.
14. Couch FJ, DeShano ML, Blackwood MA,
Calzone K, Stopfer J, Campeau L, Ganguly A,
Rebbeck T, Weber BL. BRCA1 mutations in women
attending clinics that evaluate the risk of
breast cancer. N Engl J Med 1997;336:1409-15.
15. Whittemore AS, Gong G, Itnyre J.
Prevalence and contribution of BRCA1 mutations in
breast cancer and ovarian cancer: results from
three U.S. population-based case-contol studies
of ovarian cancer. Am J Hum Genet
1997;60:496-504.
16. Langston AA, Malone KE, Thompson JD,
Daling JR, Ostrander EA. BRCA1 mutations in a
population-based sample of young women with
breast cancer. N Engl J Med 1996;334:137-142.
17. Stratton JF, Gayther SA, Russell P,
Dearden J, Gore M, Blake P, Easton D, Ponder BAJ.
Contribution of BRCA1 mutations to ovarian
cancer. New Engl J Med 1997;336:1125-1130.
18. Takahashi H, Chiu H-C, Bandera CA,
Behbakht K, Liu PC, Couch FJ, Weber BL, LiVolsi
VA, Furusato M, Rebane BA, Cardonick A, Benjamin
I, Morgan MA, King SA, Mikuta JJ, Rubin SC, Boyd
J. Mutations of the BRCA2 gene in ovarian
carcinomas. Cancer Res 1996;56:2738-2741.
19. Oddoux C, Struewing JP, Clayton CM,
Neuhausen S, Brody LC, Kaback M, Haas BL, Borgen
P, Jhanwar S, Goldgar D, Ostrer H, Offit K. The
carrier frequency of the BRCA2 6174delT mutation
among Ashkenazi Jewish individuals is
approximately 1%. Nature Genetics 1996;14:188-90.
20. Struewing JP, Abeliovich D, Peretz T,
Avishai N, Kaback MM, Collins FS, Brody LC. The
carrier frequency of the BRCA1 185delAG mutation
is approximately 1 percent in Ashkenazi Jewish
individuals. Nature Genetics 1995;11:198-200.
21. Tonin P, Weber B, Offit K, Couch F,
Rebbeck TR, Neuhausen S, Godwin AK, Daly M,
Wagner-Costalos J, Berman D, Grana G, Fox E, Kane
MF, Kolodner RD, Krainer M, Haber DA, Struewing
JP, Warner E, Rosen B, Lerman C, Peshkin B,
Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir
GM, Narod SA, Garber JE. Frequency of recurrent
BRCA1 and BRCA2 mutations in Ashkenazi Jewish
breast cancer families. Nat Med 1996;2:1179-1183.
22. Ford D, Easton DF, Bishop DT, Narod SA,
Goldgar DE, and the Breast Cancer Linkage
Consortium. Risks of cancer in BRCA1-mutation
carriers. Lancet 1994;343:692-695.
23. Struewing JP, Hartge P, Wacholder S, Baker
SM, Berlin M, McAdams M, Timmerman MM, Brody LC,
Tucker MA. The risk of cancer associated with
specific mutations of BRCA1 and BRCA2 among
Ashkenazi Jews. New Engl J Med
1997;336:1401-1408.
24. Kerlikowske K, Grady D, Barclay J, Sickles
EA, Eaton A, Ernster V. Positive predictive value
of screening mammography by age and family
history of breast cancer. JAMA
1993;270:2444-2450.
25. Burke W, Daly M, Garber J, Botkin J, Ellis
Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman
J, Petersen G, Thomson E, Varricchio C, for the
Cancer Genetics Studies Consortium.
Recommendations for follow-up care of individuals
with an inherited predisposition to cancer. II.
BRCA1 and BRCA2. JAMA 1997;277:997-1003.
26. NIH Consensus Development Panel on Ovarian
Cancer. Ovarian Cancer. Screening, treatment, and
follow-up. JAMA 1995;273:491-497.
27. Ursin G, Henderson BE, Haile RW, Pike MC,
Zhou N, Diep A, Bernstein L. Does oral
contraceptive use increase the risk of breast
cancer in women with BRCA1/BRCA2 mutations more
than in other women? Cancer Res
1997;57:3678-3681.
28. Rowley PT, Loader S, Sutera CJ, Kozyra A.
Prenatal genetic counseling for hemoglobinopathy
carriers: A comparison of primary providers of
prenatal care and professional genetic
counselors. Am J Hum Genet 1995; 56: 769-776.
29. Hoffman KJ, Tambor ES, Chase GA, Geller G,
Faden RR, Holtzman NA. Physician's knowledge of
genetics and genetic tests. Acad Med 1993;
68:625-632.
30. Surh LC, Wright PG, Cappelli M, Kasaboski
A, Hastings VA, Hunter AG, and the Molecular
Study Group. Delivery of molecular genetic
services within a health care system: Time
analysis of the clinical workload. Am J Hum Genet
1995; 56: 760-768.
31.
32. American Society of Clinical Oncology.
Statement of the American Society of Clinical
Oncology: Genteic testing for cancer
susceptibility. J Clin Oncol 1996;14:1730-1736.
33. Fraser FC. Genetic counseling. Am J Hum
Genet 1974;26:636-659.
|
